UpdatesGeneral Updates
Biocon launched Yesafili™ (biosimilar Aflibercept) in the U.S., an FDA-approved interchangeable biosimilar to Eylea® 2 mg.
Biocon LimitedBIOCON · Filed with the exchange
This expands Biocon's ophthalmology presence in a ~$5.89 billion market, offering a key treatment for eye conditions like age-related macular degeneration.
No comments yet. Be the first.